Webseite regulanet.com

Cook Medical will host several in-booth sessions as part of its commitment to further physician education and enhance the dialogue around key topics at the Society of Interventional Radiology 35th Annual Scientific Meeting. Led by prominent physicians, the sessions will cover issues impacting interventional radiology today, including the treatment of pelvic congestion, lymphatic malformations and abdominal aortic aneurysms.

In interventional procedures, it is critical that the imaging system provide outstanding image quality, as well as positioning flexibility for clinicians to access ancillary equipment and the patient quickly and easily. Toshiba America Medical Systems, Inc.'s Infinix^TM-i cardiovascular X-ray systems, featuring the unique C-arm positioner, are specifically designed to excel in this setting. Highlighting this ability, Toshiba's Infinix-i systems will be utilized during several live cases at this year's American College of Cardiology (ACC) annual meeting and i2 Summit in Atlanta, March 14 - 16, 2010. The live cases will be performed by leading physicians at Miami Children's Hospital and Memorial Hermann Heart and Vascular Institute – Texas Medical Center.

The consistency and quality of the long-term clinical results for the Endeavor^® drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT), continue to distinguish it as a treatment for coronary artery disease, according to newly released data.

The U.S. Food and Drug Administration (FDA) Neurological Devices Panel today voted seven to five to recommend approval with conditions of Deep Brain Stimulation (DBS) Therapy for Epilepsy from Medtronic, Inc. (NYSE: MDT) as adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy. If the FDA follows the recommendation of the panel, the therapy will be approved for the treatment of epilepsy in patients who have continued seizures with inadequate response to currently available epilepsy treatments.

Medical Connections Holdings, Inc. (OTCBB:MCTH), one of the nation's fastest growing healthcare staffing companies specializing in allied health, nurse and physician staffing and recruiting services, said it has executed a definitive agreement to purchase a well-respected Midwest-based healthcare staffing firm with a particular expertise in the rapidly-growing field of travel nursing.

Law Offices of Howard G. Smith announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased the common stock of Cell Therapeutics, Inc. ("Cell Therapeutics" or the "Company") (Nasdaq:CTIC) between May 5, 2009 and February 8, 2010, inclusive (the "Class Period"). The class action lawsuit was filed in the United States District Court for the Western District of Washington.

The escalating costs of cancer care combined with variations in concordance with evidence-based practice guidelines is putting the United States on a collision course for an impending collapse of its current health care system according to roundtable panelists at the NCCN 15^th Annual Conference. Clifford Goodman, PhD, of The Lewin Group, led an engaging roundtable debating the utilization of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^™) and the impact of escalating health care costs.

A new addition to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^™), the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM), was presented at the NCCN 15^th Annual Conference. Lee M. Krug, MD of Memorial Sloan-Kettering Cancer Center and a member of the NCCN Guidelines Panel discussed recommended treatment options for patients with MPM as well as first-line therapy regimens.

In the table entitled "CONDENSED CONSOLIDATED BALANCE SHEETS," the figure for "Accumulated deficit" under December 31, 2009 should read: (256,979,263) (sted (56,979,263)).

Research and Markets (http://www.researchandmarkets.com/research/3dab9d/china_pharmaceutic) has announced the addition of the "China Pharmaceutical Industry Statistics, 2000-2009" report to their offering.

Regulatory News:

Leaders of Latinos United for Healthcare (LUH), including Hispanic Federation, LULAC, NPRC, USHCC, National Hispanic Medical Association and Labor Council for Latin American Advancement (LCLAA), have sent a letter to Capitol Hill calling upon Congress to focus their attention and efforts on ensuring that the healthcare issues of Latinos are not overlooked in the final healthcare reform legislation.

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at $9.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by AVEO. The shares are expected to begin trading on the NASDAQ Global Market under the symbol "AVEO" on March 12, 2010. In addition, AVEO has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares to cover over-allotments, if any.

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results as of and for the three and twelve months ended December 31, 2009. For the three months ended December 31, 2009, the Company reported a net income of $1.1 million, or $0.05 per diluted share, compared to a net loss of $12.2 million, or $0.65 per diluted share, for the same period in 2008. For the twelve months ended December 31, 2009, the Company reported a net loss of $21.2 million, or $1.03 per diluted share, compared to a net loss of $8.0 million, or $0.43 per diluted share, for the same period in 2008. The Company ended the year with $75.1 million of cash and cash equivalents and investments.

Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Northern District of California on behalf of a class consisting of all persons or entities who purchased the common stock of Medivation, Inc. ("Medivation" or the "Company") (NASDAQ:MDVN) between July 17, 2008 and March 2, 2010, inclusive (the "Class Period").

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by certain officers and directors at Medivation, Inc. ("Medivation" or the "Company") (NASDAQ:MDVN). Medivation is a biopharmaceutical company with drugs in clinical development to treat diseases including: Alzheimer's disease, Huntington's disease, and castration-resistant prostate cancer. The Company was founded in 2003 and is headquartered in San Francisco, California.

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute (NCI) investigating the use of Avastin^® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone. A preliminary assessment of safety performed by CALGB has shown adverse events that have been previously observed in pivotal trials with Avastin. Data from the study will be submitted by CALGB for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010.

Premier Purchasing Partners, LP, today announced new agreements for reposable surgical instruments have been awarded to ConMed Corporation of Utica, N.Y.; Genicon Inc. of Winter Park, Fla.; Microline Surgical Inc. of Beverly, Mass.; and Surgical Innovations U.S., LLC of Virginia Beach, Va.

Virtual Radiologic is a national radiology practice that partners with forward-looking radiologists and hospitals to optimize radiology's pivotal role in patient care. We deliver demonstrated outcomes through unparalleled access to subspecialist expertise and our next-generation technology. Our partnerships are known for the highest standards of quality, cost efficiency and service excellence 24/7/365.

A research team led by Mayo Clinic has found a national trend toward younger, more diverse patients having total knee replacement surgery. The findings were presented today at the 2010 annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.

Research and Markets (http://www.researchandmarkets.com/research/1df5f3/european_ultrasoun) has announced the addition of Frost & Sullivan's new report "European Ultrasound Market - Upper Body Applications" to their offering.

The Bonati Spine Institute, the leading center for the patented Bonati Spine Procedures for minimally invasive laser spine surgery, congratulates Agnes Green, M.D., anesthesiologist, on her wins at the 2010 World Master's Indoor Championship in Kamloops, British Columbia, Canada last week. Dr. Green won three Silver Medals, one each in the Javelin Throw, Shot Put and Weight Throw competitions. She placed 4^th in the Hammer Throw and Discus Throw.

Crown Bioscience, Inc., a preclinical oncology CRO, announced today that Dr. Chuan (Joe) Shih has accepted the position of Executive Vice President, Integrated Drug Discovery Services Business Unit.

A collaborative project between Sanford-Burnham Medical Research Institute at Lake Nona and Analiza, Inc. has yielded aqueous solubility data for over 20,000 compounds in the NIH Molecular Library within the first 90 days of screening and characterization. The early results of the analysis are proving to be enlightening, with almost 30% of the compounds screened having low solubility – a key factor in disqualifying compounds early in the drug development process, saving later stage time and expense. The reported measurements are now part of PubChem, the largest publicly available database of bioactive molecules.

Bovie Medical Corporation (the "Company") (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company received clearance from the Food and Drug Administration (FDA) to market its ICON VS electrosurgical generator. The generator has been designed to perform vessel sealing procedures, providing both monopolar and bipolar energy options to the surgeon. The clearance of the ICON VS generator allows the Company to complete testing required in support of the previously filed vessel sealing instrument 510(k) application.

Pro-Pharmaceuticals, Inc. (OTC: PRWP.OB), a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company's Annual Report on Form 10-K which has been filed with the SEC.

Minnesota FoodShare today announced a record-breaking cash donation of $485,000 from Medtronic's employee drive to help provide food and restock 300 food shelves across Minnesota. The unprecedented donation, exceeding Medtronic's 2009 record-setting contribution of $450,000, translates into more than 2 million meals for hungry Minnesota families at a time when the growing demand for food throughout the state is sobering. Right now nearly 14 percent of Minnesota households do not have enough money to buy food.

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors. In connection with the closing, the Company issued approximately 10.0 million shares of its convertible preferred stock and warrants to purchase approximately 5.0 million shares of its common stock at an exercise price of $1.00 per share. The Company expects to close on additional gross proceeds of approximately $450,000 on or before March 15. The shares issued to the investors and the shares underlying the warrants have not been and will not be registered under the Securities Act of 1933, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release shall not be deemed an offer to sell or a solicitation of an offer to buy any securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cyanotech Corporation (Nasdaq Capital Market: CYAN) has been notified by the Nasdaq Listing Qualifications Panel that it is not in compliance with its continued listing requirements under Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) due to having only three independent directors of six total directors on its Board and fewer than three independent directors on its audit committee, while David I. Rosenthal serves as Interim President and CEO, as announced on March 1, 2010. Mr. Rosenthal has resigned from the audit committee in order to accept his interim appointment as an executive officer. Nasdaq rules require that the Board be comprised of a majority of independent directors and that the audit committee be comprised of only independent directors of which there must be at least three. The notification indicated that so long as Cyanotech provides an acceptable plan within 45 days to regain a majority of independent directors to the Board and to add a third independent member to the audit committee, NASDAQ will consider granting Cyanotech an exception for up to 180 days from March 8, 2010. Cyanotech intends to provide a plan acceptable to Nasdaq within the required time period.

Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.

Hooper Holmes (NYSE Amex:HH) today announced financial results for the fourth quarter and year ended December 31, 2009.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the 22^nd Annual ROTH Growth Stock Conference on Tuesday, March 16, 2010 at 10:30 a.m. PDT (1:30 p.m. EDT) and at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010 at 3:15 p.m. EDT.

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.

GTC Biotherapeutics, Inc. ("GTC", NASDAQ: GTCB) today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

Medical device company Vertos Medical Inc. has announced the release of positive results from its U.S. IRB I Patient Outcomes Trial, a prospective, investigational review board-approved, 75-patient study of mild* for the treatment of lumbar spinal stenosis (LSS). Six-week clinical data have shown that patients treated with mild experience statistically and clinically significant improvement in both pain and functional ability. The data also confirmed mild's safety, with no reports of patient complications related to the procedure or the devices.

Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today the appointment of Mitchell Finer, Ph.D. as Chief Scientific Officer. Dr. Finer brings over 20 years of biotech experience and is a pioneer in the field of gene therapy and regenerative medicine. At Genetix Pharmaceuticals, Dr. Finer will provide scientific leadership for the development platform capabilities and therapeutic approaches with the company's current technology platform, as well as focus on the long-term strategic scientific and clinical direction of the company.

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that management will present at two upcoming investor conferences.

Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, announced today that it has successfully completed the first commercial production of SONOVA™ 400 High GLA Safflower Oil. Seed produced by the first High GLA Safflower crop, grown during 2009, was processed to produce commercial quantities of SONOVA™ 400 oil, which is now available for distribution as a key ingredient in dietary supplements. SONOVA™ 400 is being launched at SupplyExpo 2010 being held March 12-14 in Anaheim, Calif.

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the Roth 22^nd Annual Orange County Growth Stock Conference Wednesday, March 17, 2010, at 12:00 p.m. Pacific Daylight Time. The conference is being held March 15 - 17, 2010, at The Ritz-Carlton Hotel, Dana Point, California.

Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.

LUMEDX, a leading provider of fully integrated cardiovascular information systems, announces the latest addition to its CardioPACS imaging solution: an interface to QLAB, proprietary ultrasound software from Philips. Through Philips' QLAB advanced 2D and 3D ultrasound quantification tools within the LUMEDX CardioPACS application, facilities using Philips ultrasound systems can now enjoy greater efficiencies and enhanced accuracy of diagnosis.

Schiff Nutrition International, Inc. (NYSE:WNI), is scheduled to participate in CL King's West Coast Best Ideas Conference 2010 being held at the Omni San Francisco Hotel. Bruce Wood, president and chief executive officer and Joseph Baty, chief financial officer and executive vice president, will present on Thursday, March 18^th at 9:30 a.m. PT.

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief Executive Officer and Chief Scientific Officer, will present today an overview of TLR antagonists and their applications in autoimmune and inflammatory diseases in a talk entitled "Antagonists of Toll-like Receptor 7 and 9 for Autoimmune and Inflammatory Diseases". The presentation will be made during a session called "Toll-Like Receptor Agonists and Antagonists for the Therapy of Inflammation and Infection" during the 8^th World Congress on Trauma, Shock, Inflammation and Sepsis (TSIS 2010) in conjunction with the 23^rd SIS-Europe Congress on Surgical Infections and the 2^nd Interdisciplinary Summit on Inflammation, in Munich, Germany, from March 9-13, 2010.

Victims of foodborne illness gathered in the nation's capital last week to speak to Senators about the need to move food safety legislation forward. Senate bill 510 (S510, the Food Safety Modernization Act) passed unanimously out of committee in November, but has yet to come to the floor of the Senate for a vote.

Schiff Nutrition International, Inc. (NYSE: WNI), announced it intends to discuss its fiscal 2010 third quarter results on Wednesday, March 17, 2010. The company will host a conference call at 11:00 a.m. ET, featuring remarks by Bruce Wood, chief executive officer and president, and Joseph Baty, chief financial officer and executive vice president, followed by a question and answer session.

Research and Markets (http://www.researchandmarkets.com/research/3e7491/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Prostate Cancer (Stage III)" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/223fd7/medical_transcript) has announced the addition of the "Medical Transcription Services - Global Strategic Business Report" report to their offering.

Kinmen County Magistrate Wo-Shi Lee, Kinmen County Health Bureau Director Tien-Shun Chen, Confidential Secretary Jung-Chiang Yang, Health Bureau Medical Administrative Division Head Su-Tzu Shiue and National Kinmen Institute of Technology President Chin-Cheng Lee, accompanied by NCKU Hospital Superintendent Pin-Wen Lin and NCKU Alumni Association Center Director Shih-Yu Hsiao, visited NCKU President Michael-Ming-Chiao Lai on March 8th to discuss matters related to Kinmen medical resources and future medical cooperation.

The Center for Creativity, Innovation and Entrepreneurship (CIE Center) of National Cheng Kung University, Taiwan, has inspired the thinking and imagination of many students. Four students, Yi-Cheng Chen and Kuan-Ting Tsai of the NCKU Department of Physics, together with Ya-Ju Chang of the Department of Applied Music, Tainan National University of the Arts, and Hsiang-Ting Lin of the Department of English, National University of Tainan, have established a creative studio, INNOVA, which designs innovative products for the convenience of the community.

Research and Markets (http://www.researchandmarkets.com/research/a20b7b/metals_for_biomedi) has announced the addition of Woodhead Publishing Ltd's new report "Metals for Biomedical Devices" to their offering.

NCKU Dr. Chien-Hsu Chen, Speaker of "Twenty Years Looking Back on Childhood Acute Lymphoblastic Leukemia"

Research and Markets (http://www.researchandmarkets.com/research/79a746/endocrinedisrupti) has announced the addition of Woodhead Publishing Ltd's new report "Endocrine-Disrupting Chemicals in Food" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/630d50/food_constituents) has announced the addition of Woodhead Publishing Ltd's new report "Food Constituents and Oral Health" to their offering.

Cytori Therapeutics (NASDAQ:CYTX) is reporting its financial results for the year ended December 31, 2009. More information on our commercial and clinical progress is posted online in the ‘March 2010 Shareholder Letter' at http://ir.cytoritx.com/investorrelations/blog.

Research and Markets (http://www.researchandmarkets.com/research/04bfbd/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Multiple Sclerosis (Relapsing-Remitting)" to their offering.

Despite the advances and groundbreaking research being performed in the area of cancer treatment, sometimes cancer cannot be cured. In this situation, patients and their families are faced with complex emotions and a variety of end of life issues and decisions. ABC News veteran and anchor Sam Donaldson shared his own perspective as a cancer survivor while moderating a roundtable of notable panelists at the NCCN 15^th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ on March 11, 2010.

St. Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the company's wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010.

Research and Markets (http://www.researchandmarkets.com/research/fda0b0/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Acute Heart Failure" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/d53614/distribution_agree) has announced the addition of the "Distribution Agreements in Pharma, Biotech and Diagnostics, 2nd edition" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/db2cba/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Atrial Fibrillation" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/d42515/regenerative_medic) has announced the addition of Woodhead Publishing Ltd's new report "Regenerative Medicine and Biomaterials for the Repair of Connective Tissues" to their offering. Regenerative medicine for the repair of connective tissues is a fast moving field which generates a lot of interest. The biomaterials and biomechanics for soft tissue repair has been under-represented in the past. Particularly the natural association between cartilage, tendons and ligaments is often not made. This book address this gap in the market by bringing together the natural association of cartilage, tendons and ligaments to provide a review of the different structures, biomechanics and, more importantly, provide a clear discussion of practical techniques and biomaterials which may be used to repair the connective tissues.

Nipro Corporation (Tokyo Stock Exchange and Osaka Stock Exchange Ticker Code 8086) and Home Diagnostics, Inc. (NASDAQ: HDIX) today announced the successful completion of the offer to purchase all outstanding shares of the common stock of Home Diagnostics, Inc. by Nipro's wholly-owned subsidiary, Nippon Product Acquisition Corporation (the "Purchaser").

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced its 2009 fourth quarter and full-year results, that it is further restructuring to reduce expenses, and that it is evaluating strategic alternatives to maximize shareholder value.

Research and Markets (http://www.researchandmarkets.com/research/2a470a/foodborne_pathogen) has announced the addition of Woodhead Publishing Ltd's new report "Foodborne Pathogens" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/1fe142/breast_biopsy_devi) has announced the addition of the "Breast Biopsy Devices - Global Strategic Business Report" report to their offering.

A. Malachi Mixon, III, Chairman and Chief Executive Officer, and Robert K. Gudbranson, Senior Vice President and Chief Financial Officer, of Invacare Corporation (NYSE: IVC), will present at Sidoti & Company, LLC - Fourteenth Annual New York Emerging Growth Institutional Investor Forum at The Grand Hyatt Hotel in New York City on Wednesday, March 24, 2010 at 8:00 am.

Humana Inc. (NYSE: HUM), the official health benefits provider of the PGA TOUR and the Champions Tour, will promote the benefits of walking by giving free pedometers to spectators at five PGA TOUR stops in 2010. The effort is part of the HumanaWalkIt Challenge.

Research and Markets (http://www.researchandmarkets.com/research/08ae2b/global_active_phar) has announced the addition of Frost & Sullivan's new report "Global Active Pharmaceutical Ingredients Market: An Outlook" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/9da3ff/stem_cells_researc) has announced the addition of the "Stem Cells Research - Global Strategic Business Report" report to their offering.

A new, one-touch sanitizing system designed for the hundreds of millions of Americans who wear retainers, mouth guards, night guards, dentures, and more, and struggle to keep them free from germs and odors, is now available to retailers nationwide. NatureZone™, a new product manufactured by Brain-Pad®, is a portable and handheld UV/Ozone Sanitizing Chamber that uses natural Ozone to penetrate deeply into porous materials to destroy harmful bacteria, viruses, yeasts, and molds. After a three-minute cycle, the patented combination of UV and Ozone technology kills 99.9 percent of bacteria that can lead to MRSA, Staph, Step, Salmonella, and E. Coli.

The Pennsylvania Employees Benefit Trust Fund (PEBTF) in collaboration with Bridges to Excellence (BTE) announced today a physician performance financial reward and recognition pilot program.

Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will present at the Roth OC Growth Stock Conference, which is being held March 15-17, at the Ritz-Carlton, Laguna Niguel in Dana Point, Calif.

Research and Markets (http://www.researchandmarkets.com/research/065138/south_african_heal) has announced the addition of the "South African Healthcare Market Analysis" report to their offering.

Positron Corporation (OTCBB:POSC). — Based on its recent analysis of the cardiac molecular imaging systems market, Frost & Sullivan recognizes Positron Corporation with the 2010 North American Award for New Product Innovation, for its pioneering cardiac positron emission tomography (PET) scanner, Attrius™. The Attrius™ was developed and optimized for molecular imaging of the heart, making it the ideal solution for cardiologists and hospitals looking to add high accuracy, cost effective imaging technology.

Moving to expand the evidence base for the future of structural heart disease therapy, Medtronic, Inc. (NYSE: MDT), today announced the start of the first of several new initiatives in a robust international clinical program for its CoreValve transcatheter aortic valve system, a minimally-invasive alternative to open-heart surgery for aortic valve replacement.

The New York City Fire Department (FDNY) has selected Radiation Shield Technologies' (RST) new Demron personal-protection armor as part of its commitment to improve firefighter safety, RST President Ronald DeMeo, M.D., today announced. FDNY is on the cutting edge of fire departments worldwide choosing Demron, the world's first and only fabric that provides multi-hazard protection from all nuclear, biological, chemical and bomb and ballistic threats as well as infrared radiation and heat.

22nd Annual ROTH OC Growth Stock Conference takes place March 15 - 17, 2010 at The Ritz Carlton in Dana Point, CA.

Add exhibitor profile for Adamis Pharmaceuticals Corporation to the beginning of list of 22nd Annual ROTH OC Growth Stock Conference exhibitor profiles in this release.

Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Facet Biotech Corporation (NASDAQ: FACT) (referred to as "Facet Biotech") to Abbott Laboratories ("Abbott").

IntraOp Corporation ("IntraOp") (OTC: IOPD) announced today that it has retained NewCap Partners to act as financial and strategic advisor to assist the Board of Directors and management in evaluating strategic alternatives for the Company that may enhance shareholder value. The company has identified and developed several large markets for Interoperative Electron beam Radiation Therapy ("IOERT") for the treatment of breast cancer and advanced tumors as well as External-beam Radiation Therapy ("EBRT") for the treatment of skin cancer and believes that in order to maximize these markets, additional financial resources and infrastructure will be needed in the next year to meet these market opportunities in China, Europe and North America. John Powers, President and CEO of IntraOp, stated, "Interest by prospective customers and users continues to increase in the Mobetron, our mobile electron-beam radiation therapy system, from both the IOERT and EBRT markets. In addition, we have received expressions of strategic interest in IntraOp from other healthcare companies. Accordingly, we have decided to engage a financial advisor experienced in the healthcare sector to help us evaluate our financing and strategic alternatives, which could include an investment, a manufacturing or distribution alliance, a change of control transaction or other type of transaction."

Research and Markets(http://www.researchandmarkets.com/research/d4552d/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Psoriasis" to their offering.

Research and Markets(http://www.researchandmarkets.com/research/81bdb3/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Type 1 Diabetes" to their offering.

Tenet Healthcare Corporation (NYSE:THC) today announced that Stephen L. Newman, M.D., Tenet's chief operating officer, and Biggs C. Porter, chief financial officer, will speak at Barclays Capital 2010 Global Healthcare Conference in Miami, Florida, on March 23, 2010 at 9:00 a.m. EST.

When it comes to cheering for their favorite schools during NCAA^® March Madness^®, basketball fans are being asked to put their money where their mouth is – in the Papa John's "Coaches Code Challenge" to raise money for The V Foundation for Cancer Research and The Kay Yow/WBCA Cancer Fund.

Research and Markets(http://www.researchandmarkets.com/research/69baf7/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Asthma" to their offering.

The most decorated U.S. Winter Olympian in history, star of the 2010 Winter Olympic Games and Seattle native, Apolo Anton Ohno has partnered with The Century Council and its Ask, Listen, Learn: Kids and Alcohol Don't Mix program. Today in Bellevue, Ohno, in conjunction with the newly formed Apolo Anton Ohno Foundation, made his final stop on a five-city tour to schools throughout the U.S. encouraging kids to say "YES" to a healthy lifestyle and "NO" to underage drinking. The Apolo Anton Ohno Foundation, established by the eight-time Olympic medalist, will focus on providing youth of all ages and socio-economic backgrounds with the opportunity to play sports, be active and learn about the benefits of making responsible and positive choices.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that GlaxoSmithKline (NYSE: GSK) was granted marketing authorization from the European Commission (EC) for Revolade^® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). Eltrombopag is indicated for adult chronic ITP splenectomized patients who have not responded (are refractory) to other treatments, such as corticosteroids and immunoglobulins. Eltrombopag may also be considered as second-line treatment for adult non-splenectomized patients where surgery is contraindicated.

Research and Markets (http://www.researchandmarkets.com/research/251b4a/healthcare_it_a_m) has announced the addition of GlobalData's new report "Healthcare IT: A Market Poised for Strong Growth in the Future" to their offering.

Research and Markets(http://www.researchandmarkets.com/research/d8c468/investment_opportu) has announced the addition of GlobalData's new report "Investment Opportunities in the Medical Devices Sector" to their offering.

MDI Healthcare Solutions, based in Ponte Vedra, Florida, announced today that the second-generation E.A.R.L.®, part of the MDI Analytics Suite, will be featured in the keynote address at Microsoft's MIX10, The Next Web Now Conference in Las Vegas on Monday, March 15^th (http://live.visitmix.com). The MDI Analytics Suite is a collection of practical data visualization and analytics solutions for the complex healthcare environment. E.A.R.L.® (Empowered Analysis and Reporting Log) was created with Microsoft Silverlight, a browser plug-in that powers rich interactive experiences through Web, desktop and mobile applications.

Research and Markets(http://www.researchandmarkets.com/research/9358b8/sterilization_wrap) has announced the addition of GlobalData's new report "Sterilization Wraps: A Market Snapshot" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/6f4000/interference_screw) has announced the addition of GlobalData's new report "Interference Screws for ACL - PCL Reconstruction: An European Market Snapshot" to their offering.

Using risk stratification to assist in treatment selection was just one of the focal points at a recent presentation of the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines^™) for Acute Myeloid Leukemia (AML) at the NCCN 15^th Annual Conference. B. Douglas Smith, MD of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a member of the NCCN Guidelines Panel for AML, spoke about the challenges in treating AML as well as recent updates to the NCCN Guidelines^™.

The National Minority Quality Forum (The Forum) is launching a new public information campaign aimed to help educate consumers, physicians, and policymakers about the risks associated with prescribing and taking unapproved drugs that have not been subjected to the rigorous Food and Drug Administration's (FDA) review and approval process. Unapproved drugs can be dangerous – or even deadly – to patients as a result of the lack of testing, unknown or unregulated ingredients, improper labeling, and as a result of this lack of information, the inability to predict drug to drug interactions.

Sanofi-aventis U.S. and Bristol-Myers Squibb Company (NYSE: BMY) today announced revisions to the U.S. prescribing information for PLAVIX® (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active metabolite. These patients, who are designated as poor metabolizers, represent, according to the prescribing information, approximately 2% of whites, 4% of blacks, and 14% of Chinese. The percentage of poor metabolizers is estimated to be approximately 3% of the population, based on published studies.

Sorin Group, (MIL:SRN)(Reuters Code: SORN.MI), a global company and a leader in the treatment of cardiovascular diseases, announced today that it has reached a tentative settlement of the previously disclosed 2006 United States Department of Justice investigation into sales and marketing practices of its subsidiary Ela Medical Inc. and of former independent sales representatives. Settlement is subject to completion of negotiations and approval of a definitive agreement and corporate integrity agreement with the Department of Justice and Office of Inspector General of the Department of Health and Human Services.

Medical Properties Trust, Inc. (NYSE: MPW) announced today that a State District Court jury in Harris County, Texas rejected all claims brought against the company and other entities by a group of physicians whose efforts to create and operate a new hospital in Houston failed in 2006.

Natus Medical Incorporated (Nasdaq:BABY) today announced that Jim Hawkins, President and Chief Executive Officer of the Company, will make a presentation at the Roth Capital Partners 22nd Annual OC Growth Stock Conference. The conference is being held at The Ritz-Carlton in Laguna Niguel, California. Mr. Hawkins is scheduled to present at 10:00 a.m. Pacific Time (1:00 p.m. ET) on Monday, March 15, 2010.

Aetna (NYSE: AET) announced today that members of its senior management team will present at the Company's institutional investor conference in New York City on March 19, 2010 beginning at 8:30 a.m. EDT and concluding at 12:00 p.m. EDT.

Medafor Inc. announced today that it has signed a long-term raw material supply agreement with Magle Life Sciences of Sweden, the supplier of the key powder component for Medafor's patented MPH(R) (Microporous Polysaccharide Hemosphere) surgical product, which is used by surgeons to control bleeding in complex surgical operations. Magle manufactures the degradable starch microsphere (DSM-A) specified and tailor made to achieve rapid hemostasis in the human body.

HHS Secretary Kathleen Sebelius and National Coordinator for Health Information Technology (HIT) Dr. David Blumenthal will hold a press conference call on Monday, March 15, 2010 to discuss new investments in Health Information Technology (HIT) in communities throughout the United States.

February 23, 2010 marked the 1^st anniversary for the Carol Milgard Breast Center. During this first year, nearly 50,000 women from the region received state of the art breast imaging through the Center. Not only was the Center successful in reaching the communities it serves, but it also succeeded in greatly reducing the time from when a woman receives her mammogram to the time she receives her exam results.

Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration (FDA) has allowed an IND (Investigational New Drug) for the Company's lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials. The IND review process was performed by the FDA's Division of Oncology Products and involved a comprehensive review of data submitted by the Company covering pre-clinical studies, safety, chemistry, manufacturing and controls, and the protocol for the Phase I clinical trial.

Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, today reported financial results for the three and six months ended January 31, 2010.

Coughlin Stoia Geller Rudman & Robbins LLP ("Coughlin Stoia") (http://www.csgrr.com/cases/cellthera/) today announced that a class action has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of the common stock of Cell Therapeutics, Inc. ("Cell Therapeutics " or the "Company") (NASDAQ: CTIC) between May 5, 2009 and February 8, 2010, inclusive (the "Class Period"), seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act").

The U.S. Department of Health and Human Services today celebrated the opening ceremonies of the 2010 Paralympic Games by releasing new Web videos promoting First Lady Michelle Obama's national initiative, Let's Move!, to solve the problem of childhood obesity within a generation. In the new videos, 2002 gold medalist in sled hockey Manny Guerra and world champion monoskier Peter Axelson discuss why it is important for people with disabilities to be active, and how all Americans can be sports champions.

Exactly two months after the earthquake in Haiti, the American Refugee Committee warns that many more people may die from the spread of diseases brought on by the fast-approaching rainy season.

PanGenex Corporation (Pink Sheets:PGCX) ("PanGenex" or "the Company") a global manufacturer and distributor of nutraceutical and dietary supplement products, announced today that demand for its proprietary products exceed its short term ability to fill orders. The sales momentum continues to build on top of previously announced records for the fourth quarter of 2009.

American HomePatient, Inc. (OTCBB: AHOM), one of the nation's largest home health care providers, today announced that it has entered into an ninth forbearance agreement with NexBank, SSB, the agent for its senior debt (the "Agent"), and the holders in interest of a majority of the senior debt (the "Forbearance Holders").

Teleflex Incorporated provided an update today on the previously announced Arrow International, Inc. voluntary recall of ALL lots of its Arrow custom intravenous administration products (IV tubing sets and accessories) and certain Arrow arterial embolectomy catheters distributed prior to February 19, 2010 .

ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today reported that A. Ernest Whiton, its Chief Financial Officer and Vice President of Administration, is entering into a 10b5-1 sales plan for the sale of shares of ZOLL common stock over an approximate 12-month period. Under the plan, it is anticipated that approximately 60,000 shares will be sold but it is possible that under certain market conditions, the number of shares sold under the Plan may increase to up to 90,000 shares. Sales under the plan are expected to commence in the third quarter of fiscal 2010. The shares to be sold will be acquired upon the exercise of a portion of stock options which were granted to Mr. Whiton over the past eight years. This new plan follows 10b5-1 sales plans entered into by Mr. Whiton in 2006, 2007 and 2008.

In second graf, third sentence the link should read http://www.csgrr.com/cases/cellthera/ (sted: http://www.csgrr.com/cases/celltherapeutics/).

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced today favorable clinical trial results from the MASCOT Trial, an important study evaluating the AngioSculpt® PTA Scoring Balloon Catheter for the treatment of femoro-popliteal PAD (peripheral artery disease).

Research and Markets (http://www.researchandmarkets.com/research/bbaae2/systemic_fungal_in) has announced the addition of Frost & Sullivan's new report "Systemic Fungal Infection Therapeutics Research Malaysia" to their offering.

A board-certified pediatrician joined Pinnacle Medical Group's Rialto, California office on March 1, 2010.

Human Genome Sciences, Inc. (Nasdaq: HGSI) and BioInvent International AB (OMXS: BINV) today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced, as required by NASDAQ Marketplace Rule 5250(b)(2), that the report of the Company's independent registered public accounting firm, included in its previously filed consolidated financial statements for the fiscal year ended December 31, 2009, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2010, contained an explanatory paragraph expressing substantial doubt regarding the Company's ability to continue as a going concern. This announcement does not represent any change or amendment to the Company's fiscal year 2009 financial statements or to its Annual Report on Form 10-K.

Mehr als 1.700 Vertreter von 1.061 Unternehmen haben an der vierten Ausgabe der jährlichen Partnering-Konferenz BIO-Europe Spring^® teilgenommen, die vom 8. bis 10. März im Internationalen Kongresszentrum in Barcelona (CCIB) stattfand. Der Event erbrachte erneut den Nachweis, dass mit der Einführung der BIO-Europe Spring im Jahr 2007 die richtige Veranstaltung zum richtigen Zeitpunkt geschaffen wurde, um dem wachsenden Interesse an einem großen und produktiven Partnering-Event Rechnung zu tragen.

Primordial, a leading vendor of communications, workflow, quality management and analytics applications for the medical imaging market, and Charlotte Radiology, one of the largest radiology groups in the United States, announced today a partnership to deploy and further develop Primordial's applications for use by Charlotte Radiology physicians across numerous hospitals and imaging centers.

BioInvent International AB (STO:BINV) and Human Genome Sciences, Inc. (NASDAQ:HGSI) today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.

SpineUniverse, a Vertical Health website, proudly introduces the Community Case Discussion for its network of spine professionals. This interactive forum allows spine specialists to engage with one another in the SpineUniverse Spinal Case Study Library.

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the 22^nd Annual Roth OC Growth Stock Conference on Wednesday, March 17, 2010 at 12:30 p.m. ET (Eastern Time).

In hybrid catheterization procedures it is crucial that the imaging system provides the flexibility to quickly and easily access both the patient and ancillary equipment. To form its new hybrid catheterization suite, Miami Children's Hospital, a pioneer in hybrid procedures, recently installed Toshiba America Medical Systems's Infinix^TM CF-i bi-plane system with the new CAT-880B hybrid catheterization table. When combining the five-axis positioner of the Infinix-i system with the tilting and cradling features of the hybrid table, physicians are able to obtain optimal image angles while having unprecedented access to patients. Miami Children's Hospital will use its new hybrid cath lab for complex interventions on patients of all sizes, from newborns to young adults.

As competition in the voluntary market continues, carriers wanting to gain or maintain market share in the market need an in-depth understanding of all their customers, from the distributor to the employee and employer. Eastbridge Consulting Group's latest study, MarketVision^TM—The Employer Viewpoint Update©, focuses specifically on the employer customer group. The study results are based on quantitative interviews with plan administrators in accounts ranging from 10 to more than 5,000 employees. The topics covered include:

Precision BioSciences, Inc., today announced that the Opposition Division of the European Patent Office (EPO) has issued a written decision confirming its November 18, 2009 revocation of the previously granted claims of Cellectis' European Patent No. 1 485 475. As previously reported, after an oral hearing in an Opposition Proceeding initiated by Precision BioSciences, Cellectis' previously granted claims to single-chain meganucleases, including those derived from I-CreI, as well as Cellectis' claims to most classes of hybrid meganucleases, were revoked in their entirety. As a result of the interlocutory decision, Cellectis' patent has been severely restricted such that it now includes only claims limited to hybrid meganucleases formed by the fusion of an N-terminal of the I-DmoI meganuclease to a domain derived from the I-CreI meganuclease.

Sanomedics International Holdings, Inc. (Pink Sheets:SIMH) has announced that the company has signed a comprehensive distribution agreement with Watermark Medical, LLC. The company will immediately provide Sanomedics access to their expanding global distribution network.

Rex Medical, L.P., today announced that it has received 510(k) Clearance from the U.S. Food and Drug Administration (FDA) for the Cleaner™ Rotational Thrombectomy System. Cleaner™ technology is indicated for mechanical declotting of occluded native vessel dialysis fistulae and synthetic dialysis access grafts. Argon Medical Devices, Inc. will lead all marketing and distribution efforts for Cleaner™ in the United States, European Union and Canada.

Order Optimizer, a leading provider of inpatient CPOE, Decision Support, and Evidence-Based Protocols, announced deployment of its software at St. Joseph Hospital in Eureka, California. The go-live date of February 3, 2010, was met successfully after the completion of a short 9-week implementation period. A HITECH Act certified solution, Order Optimizer prepares St. Joseph Hospital to qualify for incentive funding under the American Recovery and Reinvestment Act of 2009 (ARRA).

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate). All patients enrolled in the trial used Gleevec for at least one year and still had cancer cells present. The study was conducted by researchers at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, led by Hyam Levitsky, M.D., professor of oncology, medicine and urology at the Cancer Center. The research was funded by the National Institutes of Health.

Cross Country Healthcare, Inc. (Nasdaq:CCRN) announced today that it is scheduled to make a presentation on Wednesday, March 24, 2010, at 3:15 p.m. Eastern Time at the Barclays Capital 2010 Global Healthcare Conference being held at the Lowes Miami Beach Hotel in Miami Beach, Florida.

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that Hoji Alimi, the company's CEO and founder, will present a corporate overview and business update at the Roth Capital Partners 22nd Annual OC Growth Stock Conference to be held at the Ritz Carlton in Laguna Niguel, California. Mr. Alimi's presentation is scheduled on Wednesday, March 17, 2010 at 1:30 p.m. PDT, with a breakout session to immediately follow.

As the incidence of diabetes and hypertension continues to grow worldwide – and increasing numbers of patients progressing to kidney disease and kidney failure place a financial strain on public health systems – the need for early patient education about kidney disease and treatment options, including home-based treatments, has become critical.

Pro-Pharmaceuticals, Inc. (OTCBB: PRWP) (the "Company"), today announced that it has closed a $335,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.1 million.

The UnitedHealthcare Children's Foundation (UHCCF) is seeking grant applications from families in need of financial assistance to pay for their child's health care treatments, services or equipment not covered by their commercial health insurance plans.

MEDNAX, Inc., (NYSE: MD) today announced the acquisition of Maryland Perinatal Associates, PC, a group of four maternal-fetal medicine physicians based in Rockville, Maryland.

OXIS INTERNATIONAL, INC. (Pink Sheets: OXIS, Paris: OXI) is extremely proud to announce that Bernie Landes has joined the company as its President. Mr. Landes has over 30 years of experience in the nutraceutical and functional foods industry. Most recently Mr. Landes served as the President of the Nutritional Products Consulting Group serving a global client base in the areas of scientific, regulatory commercialization and M&A activity.

Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, announced today that an overview of the Company's business strategy will be given at the 22^nd Annual ROTH Capital Markets Conference on Monday, March 15, 2010, at 8:00 am Pacific Time. The conference is being held at the Ritz-Carlton Hotel in Laguna Niguel, California.

LIVESTRONG^SM.COM , a destination for health, fitness and lifestyle-related information, has revealed new features for MyPlate, the site's popular lifestyle management tool. These site enhancements include new features such as relevant content pop-ups, custom recipe builders, and expanded food and activity databases, all of which are designed to bolster LIVESTRONG.COM's position as the leading online health and fitness tool.

Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging; exhibited its CT Laser Mammography (CTLM®) system at the European College of Radiology, March 4-8, 2010, in Vienna, Austria. ECR 2010 had over 19,000 international delegates, an increase of attendance over the previous years.

St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) clearance and European CE Mark approval for the Engage™ and Engage TR™ Introducers. Introducers are the starting point of cardiac catheterization for diagnostic and interventional procedures, helping physicians to safely gain and maintain vascular access.

AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today that it will report its fiscal 2010 third quarter financial results on Thursday, April 1, 2010, after the close of the financial markets.

Tenet Healthcare Corporation (NYSE: THC) today announced that 20 of its hospitals have been designated as Blue Distinction Centers for Spine Surgery and/or Blue Distinction Centers for Knee and Hip Replacement by local Blue Cross and Blue Shield companies.

CPM Marketing Group (CPM), the market leader for healthcare customer relationship management (CRM) and strategic marketing solutions, announced today three separate honors in the 7th annual Service Industry Advertising Awards (SIAA) for healthcare marketing campaigns. Two of the three awards were garnered for campaigns it implemented on behalf of its hospital clients. These awards recognize the nation's most creative and best communication accomplishments of the service industry.

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor (Maria) in Poland as a site to irradiate highly-enriched uranium targets for Molybdenum 99 (Mo 99) production. Covidien will use the Mo 99 obtained from Maria in the manufacture of its Technetium 99m (Tc 99m) generators. Patients should begin to benefit from Maria-produced Mo 99 in the United States and Canada later this month.

March 11, 2010--Senomyx, Inc. (NASDAQ: SNMX), a leading company focused on using proprietary taste receptor technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Kent Snyder, the Company's Chief Executive Officer, will present a corporate overview on Tuesday, March 16, 2010 at 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time) during the ROTH 22nd Annual OC Growth Stock Conference. The conference is taking place at the Ritz Carlton Laguna Niguel in Dana Point, CA. During the presentation, Mr. Snyder will discuss corporate developments including the Company's pipeline of novel flavor ingredients and its business strategy.

SCA Tissue North America, a global personal hygiene product company and one of the most sustainable companies in the world, today announced the release of The Tork^® Report: Healthy People, Healthy Planet^™--a unique report that highlights recent consumer research on hygiene practices and business owner attitudes regarding environmentally responsible business operations.

Emerging Healthcare Solutions, Inc. (Pink Sheets: EHSI) was pleased on learning the news that Intel, The Mayo Clinic and GE Healthcare have launched a new initiative to study the care and cost benefits of home-based telemedicine for elderly patients with chronic illnesses. Emerging Healthcare Solutions has licensed a cutting-edge mobile telemedicine platform from Telemedicus, Inc., which the Company is currently developing for marketing. The Telemedicus system was jointly developed by the University of Texas Health Science Center at Houston and Texas A&M University before it was purchased by Telemedicus, Inc.

DR Systems, one of the most respected names in healthcare information systems, announced today that it is introducing the Unity™ Cardiovascular Information System (CVIS) this month at the upcoming annual meeting of the American College of Cardiology, ACC.10.

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has donated $140,000 of its QuikClot® Emergency Dressing™ and QuikClot Combat Gauze™, the company's life-saving hemostatic agents, for use in Haiti and other future disaster relief efforts by AmeriCares, a nonprofit global health and disaster relief organization. Z-Medica has also shipped an additional order of 34,000 units of its QuickClot® Combat Gauze™ from the United States Department of Defense, also to be used to provide medical treatment in Haiti. The United States Department of Defense currently uses QuickClot® Combat Gauze™ as the official first-line hemostatic treatment for all branches of the United States military and recently this product was named a "Top Ten Greatest Invention of 2008" by the U.S. Army Materiel Command.

Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that it recorded total revenues of $9,946,269, an increase of 69% compared to $5,876,337 in 2008. Clinical products revenue for the year ended December 31, 2009 increased 85% to $6,828,651 compared to $3,683,706 in 2008.

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics' ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators. Brentuximab vedotin, an ADC that utilizes the vcMMAE drug-linker unit, is in a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for relapsed and refractory systemic anaplastic large cell lymphoma. The company anticipates submitting a New Drug Application for brentuximab vedotin in the first half of 2011.

Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix's branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea, China and Japan.

Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it has entered into privately negotiated agreements with certain institutional holders of an aggregate of approximately $47 million in face value of its 2.625% senior convertible debentures due 2024 to exchange the debentures held by such holders for a like face amount of newly issued 10.125% senior convertible debentures, due 2014. The remaining $31 million outstanding face amount of the 2024 debentures will remain outstanding.

Tahitian Noni International (TNI) announced that Tahitian Noni^® Bioactive Beverages™ contain iridoids—a bioactive compound linked to over two dozen real health benefits. Iridoids have been studied by scientists for over 50 years, and now 12 unique iridoids have been identified in the noni fruit.

ZymoGenetics, Inc. (NASDAQ:ZGEN), today announced that A. Bruce Montgomery, M.D., was named to the company's Board of Directors.

Fiberlink Communications Corporation, the creator and developer of cloud-based Mobility as a Service (MaaS) solutions, today announced the Healthcare IT Compliance Service™, a comprehensive business intelligence reporting platform for healthcare and life sciences organizations. The MaaS360^® Healthcare IT Compliance Service gives IT professionals a single, unified view of policy and status reporting for all their mobile devices, helping organizations to identify and manage compliance vulnerabilities and data security risks.

"Managing and Securing Mobile Healthcare Data and Devices," a commissioned technology adoption profile conducted by Forrester Consulting on behalf of Fiberlink Communications Corporation was released today with findings on the top needs of healthcare IT leaders. With 95% of healthcare enterprises relying on smartphones for work, this industry is one of the most mobile across all verticals.

Hythiam, Inc. (OTCBB:HYTM) announced today the updated time and date of the Company's conference presentation. Rick Anderson, President and Chief Operating Officer of Hythiam, will be presenting at the Roth Capital Partners 22^nd Annual OC Growth Stock Conference on Wednesday, March 17, 2010 at 9:30 a.m. PDT. The event will be held March 15-17, 2010 at the Ritz-Carlton in Dana Point, California. Hythiam's presentation will also be available on its website at www.hythiam.com.

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), has been recognized as one of FORTUNE Magazine's Most Admired Companies in 2010 for the fifth consecutive year. This year, DaVita® ranked first among Health Care Medical Facilities overall, and was specifically recognized in the magazine's categories of Innovation, Use of Corporate Assets, Financial Soundness, Long-Term Investment and Quality of Products and Services.

Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results of the three- and twelve-months periods ended December 31, 2009.

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the quarter ended January 31, 2010.

EAGLE EYES® Optics and NASA's Jet Propulsion Laboratory will be inducted into the Space Technology Hall of Fame® for their radiation-filtering technology - used in EAGLE EYES polarized sunglasses to protect human eyes from solar radiation. The Space Technology Hall of Fame® honors outstanding technologies developed for use in space and adapted to improve life on Earth. EAGLE EYES will be recognized at a private ceremony at the 26th National Space Technology Hall of Fame® Symposium in Colorado on April 15th. The Space Technology Hall of Fame® was created in 1988 by the Space Foundation (www.spacefoundation.org), in cooperation with NASA, to increase public awareness of the benefits resulting from space exploration programs. To date, the Space Foundation has inducted 61 technologies, honoring the organizations and individuals who transformed space technology into commercial products that improve the quality of life for all humanity.

Global Hunter Securities ("Global Hunter") today announced that Michael Tu has joined the company's research department as vice president and senior analyst, healthcare. Tu will focus on Global Hunter's expanding coverage of healthcare companies, including those which are based in China and the U.S.

Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company's 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

Food Safety attorney William Marler is calling for enforcement of a federal law that allows criminal sanctions to be imposed against food manufacturers that can prevent harmful food products from being distributed, but do not do so. The Federal Food, Drug, and Cosmetic Act (FD&C Act) is one of the federal government's primary enforcement tools to prevent the distribution of contaminated or "adulterated" food.

Geoff Cole of the Brain Training Centers of Florida (BTC) has earned the Masters Level II Certification for brain training utilizing the Brain Wave Optimization with Real Time Balancing™ technology of Brain State Technologies. He now is the only Master level or higher certified brain trainer in Florida. To achieve this certification, a brain trainer must complete over 2,000 brain training session hours, complete more than 60 hours of educational seminars, and pass two masters level examinations. Whereas, Mr. Cole has completed more than 4,000 training hours, he is awaiting additional testing and session audits to achieve higher Masters Level Certifications. He expects to reach Masters Level III by September of this year.

Automated reminder and follow-up calls for HPV vaccinations increase adherence rates from 5% to over 20%, according to a new white paper published by iReminder, LLC. The Scotland National Health Service is the leader in HPV vaccination compliance, with rates as high as 92% for the first dose and 87.8% for the second dose. The laggard is Mississippi, USA where HPV vaccination rates are as low as 15.8%.

MedPro Safety Products, Inc. (OTCBB:MPSP), a leading developer of transformational technologies that enable safer medication delivery and blood collection, has entered into a Joint Development Agreement (JDA) with Belgium-based Helvoet Pharma for the technical development and commercialization of MedPro's pre-filled safety syringe (PFSS).

Broadlane, Inc., the leading end-to-end cost-management partner for healthcare providers, today launched Prolucent™ Workforce Management to help hospitals navigate the unprecedented staffing challenges expected to accelerate as the first baby boomer turns 65 less than a year from now. Broadlane, which entered the clinical workforce management space eight years ago, believes that it will be imperative for hospitals to mitigate the challenges driven by the aging population and retiring workforce by increasing workforce efficiency and productivity with proven clinical staffing technologies, services and strategies.

ACM Global Central Laboratory, the global central lab that continually defines the customer-service standard with its flexible approach, and BioClinica™Inc., (NASDAQ: BIOC) a global provider of clinical trial management services, are pleased to announce they are co-sponsoring the upcoming R&D Directions webinar on, "How Central Lab and Electronic Data Capture Providers Can Collaborate Effectively." Chris Helton, director, Data Management and Clinical Systems at ACM Global and Jonathan Andrus, VP, Data and Study Operations at BioClinica will present specific opportunities to improve collaboration and integration between EDC and central lab data.

Please be advised that Gallup and Healthways, Inc. (NASDAQ: HWAY) today released the Gallup-Healthways Monthly U.S. Well-Being Report for February 2010.

Illumina, Inc. (NASDAQ:ILMN) today announced that it has sequenced the DNA of American actress Glenn Close, the first publicly named female to have her DNA sequenced to full coverage. The service was completed in Illumina's CLIA certified and CAP accredited laboratory utilizing Illumina's Genome Analyzer technology and following the established process shown at http://www.everygenome.com/. Ms. Close's DNA was sequenced to an average depth greater than 30 fold, providing information on SNP variation and allowing for the analysis of other structural characteristics of the genome such as insertions, deletions and rearrangements. Specifically, over 95% of the known genome was reported, including over 12 million genotype calls on previously documented SNPs. In addition, 379,000 SNPs previously not reported in any public database were found.

Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported financial results for the fourth quarter and full year ended December 31, 2009.

CytoCore Inc. (OTCBB:CYOE), the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, announced today that NeoMed has made an investment in CytoCore Inc.

Muscle Flex Inc. (www.MuscleFlex.com) (Pink Sheets:MFLI) announced today that it will create a separate wholly owned division of the company for the television and media industry. The new BRAVADA / Muscle Flex division will engage solely in the creation and development of television programming as well as compelling entertainment content for related media.

Is there a technology that can put you at the top of your game and eliminate stress at the same time? Yes, for scores of executives and business elites, "Inner Engineering" is that technology. In a rare opportunity the pioneer of "Inner Engineering", Sadhguru J. Vasudev, named one of India's 50 most powerful people, will offer his breakthrough methodology on April 8-11, 2010 at the Ritz Carlton in Marina Del Rey.

Annual Report and discharge from liability The company's Income Statement and Balance Sheet were adopted and the Board of Directors and the Chief Executive Officer were discharged from liability for the financial year 2009.

Research and Markets (http://www.researchandmarkets.com/research/4068f0/advances_in_teleim) has announced the addition of Frost & Sullivan's new report "Advances in Teleimaging Systems (Technical Insights)" to their offering.

Fiberlink Communications Corporation, der Schöpfer und Entwickler von Cloud-basierten Mobility-as-a-Service- bzw. MaaS-Lösungen meldete heute die Einführung des Healthcare IT Compliance Service™, einer umfassenden Business-Intelligence-Plattform für Unternehmen und Organisationen im Gesundheitswesen und im Bereich der Lebenswissenschaften. Der MaaS360^® Healthcare IT Compliance Service gibt IT-Fachleuten einen einheitlichen Komplettüberblick über Auflageneinhaltung und Status aller mobilen Endgeräte in ihrer Zuständigkeit. Schwachpunkte bezüglich Vorschriftenkonformität und Datenschutzrisiken können also prompt ermittelt und behoben werden.

Research and Markets (http://www.researchandmarkets.com/research/144a81/medical_equipment) has announced the addition of GlobalData's new report "Medical Equipment Annual Deals Analysis 2010" to their offering.

Bravo Wellness, a provider of results-based incentives for wellness, announced that MasterBrand Cabinets, Inc., its 50^th customer, selected Bravo Wellness to implement its wellness initiatives for its 5,700 US employees.

While choking hazards in toys have been widely publicized and addressed by the Consumer Product Safety Commission (CPSC), ironically choking hazards in food have lacked federal attention despite the fact that food is far more likely to go into a child's mouth. Intertek, a leading provider of quality and safety solutions for a wide range of industries worldwide, has contributed to a recently released policy statement by the American Academy of Pediatrics (AAP) urging the U.S. Food and Drug Administration (FDA) to establish a systematic process for examining and addressing the hazards of food-related choking to mandate improvements to food design.

Research and Markets (http://www.researchandmarkets.com/research/0fb1f2/pharmaceutical_pri) has announced the addition of Decision Resources, Inc.'s new report "Pharmaceutical Pricing, Reimbursement, and Market Access News in the Fourth Quarter of 2009" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/b903c4/antivirals_novel) has announced the addition of Decision Resources, Inc.'s new report "Antivirals: Novel Targets, Technologies, and Dealmaking" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/08d963/state_of_the_pharm) has announced the addition of Decision Resources, Inc.'s new report "State of the Pharmaceutical Industry, 2010 - Critical Role of Midsize Pharma" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/1ae183/albany_ny_healt) has announced the addition of the "Albany, NY - Healthcare Market Overview" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/995cff/pharmaceuticals_e) has announced the addition of the "Pharmaceuticals: Europe Industry Guide" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/e1b885/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Epilepsy" to their offering.

NMT Medical, Inc. (NASDAQ: NMTI) today announced the completion of its Scientific Advisory Board (SAB), which is composed of eight industry leading experts from the cardiovascular and neurological medical communities. The SAB will meet periodically with our scientific and development personnel as well as members of the Company's executive management to discuss and advise the Company on its ongoing and future clinical, regulatory and development programs, including its pivotal patent foramen ovale (PFO)/stroke and transient ischemic attack trial, CLOSURE I.

Research and Markets (http://www.researchandmarkets.com/research/a14b3e/materials_science) has announced the addition of Woodhead Publishing Ltd's new report "Materials Science for Dentistry" to their offering.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2009 financial results, provided an update on recent progress with its programs, and announced 2010 objectives.

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the appointment of William Kaelin Jr., M.D., to its scientific advisory board. Dr. Kaelin currently serves as a Professor of Medicine at Harvard Medical School. Dr. Kaelin's laboratory focuses on tumor suppressor genes and the normal functions of the proteins they encode.

Research and Markets (http://www.researchandmarkets.com/research/c266c9/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Bipolar Depression" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/fdb853/drugdevice_combin) has announced the addition of Woodhead Publishing Ltd's new report "Drug-Device Combination Products" to their offering.

The Turkish American Chamber of Commerce & Industry, Midwest holds its second annual Medical Tourism conference "Globalization and Model Partnership in Healthcare: United States and Turkey" at Chicago Marriott Hotel downtown, March 12-13, 2010.

Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its fourth-quarter and year-end 2009 financial results after the close of the market on Tuesday, March 16, 2010. The Company plans to hold a conference call the next day (Wednesday, March 17) at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the Company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the Company, some of the responses to which may contain information that has not been previously disclosed.

Research and Markets (http://www.researchandmarkets.com/research/ff2bff/epigenetics_glob) has announced the addition of the "Epigenetics - Global Strategic Business Report" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/c692f2/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Parkinson's Disease" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/3559e8/systemic_fungal_in) has announced the addition of Frost & Sullivan's new report "Systemic Fungal Infection Therapeutics Market - Australia" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/2aca55/bladder_cancer_the) has announced the addition of the "Bladder Cancer Therapeutics - Global Strategic Business Report" report to their offering.

Blue Spoon Consulting Group, LLC, today published its design for an industry ecosystem to change the effect of asthma worldwide. Available for download through the Blue Spoon Consulting website (www.bluespoonconsulting.com), the ecosystem makes novel linkages between industry players to create new health and economic value. The strategy innovation is centered on designing systemic collaboration around shared marketspace, unifying stakeholders to simultaneously grow business and improve health outcomes.

Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first proven non-surgical permanent birth control method available, today announced that Gregory Lichtwardt, executive vice president and chief financial officer, will present at the Roth OC Growth Stock Conference on Monday March 15, 2010, at 10:30 a.m. PST. The conference will be held at the Ritz-Carlton Laguna Niguel, Dana Point, California.

Bond International Software, the world's premier supplier of staffing software solutions, recently signed a contract with i3 Pharma Resourcing, a leading global provider of quality clinical research and data services personnel. i3 will replace a number of disparate databases throughout its global operations with Bond's flagship software, Adapt.

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063. The data were presented today at the 8^th World Congress on Trauma, Shock, Inflammation and Sepsis (TSIS) in Munich, Germany. TSIS is a medical conference which focuses on the latest knowledge, developments and innovative concepts related to the recognition of disease as well as patient care and therapy within the wide field of acute and chronic systemic inflammation.

Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be exhibiting its over-the-counter (OTC) and prescription pain relievers, Nyloxin OTC and Nyloxin Rx, at the 12^th IDGA Battlefield Healthcare Summit in Washington, D.C. The IDGA Battlefield Healthcare Summit is considered one of the premier military healthcare conferences and the start to the IDGA's Military Health Week.

Angeion Corporation (NASDAQ: ANGN) today announced that it has entered into an agreement to serve as the official supplier of metabolic and endurance training systems for Team Garmin-Transitions, the American professional cycling team dedicated to ethical sporting and developing the next generation of cycling champions.

Research and Markets (http://www.researchandmarkets.com/research/de5090/antimigraine_drug) has announced the addition of the "Anti-Migraine Drugs - Global Strategic Business Report" report to their offering.

Intracorp (International Rehabilitation Associates, Inc.), a subsidiary of CIGNA Corp. (NYSE:CI), has earned full accreditation from URAC for the company's case management and utilization management programs. The accreditations, which are effective for three years, recognize the quality of these programs.

Frederick Memorial Healthcare System, of Frederick, Md. achieved more than $5 million in labor cost savings with the Premier healthcare alliance through the use of LaborConnect™, Premier's labor management program.

The Food Allergy & Anaphylaxis Network (FAAN) is thrilled to honor more than a dozen individuals and institutions that have shown an admirable commitment to food allergy safety, awareness, and education, through its 14th Annual Mariel C. Furlong Awards for Making a Difference (MCF), Second Annual Grandparent Awards, and Seventh Annual Special Achievement Awards.

St. Jude Medical, Inc. (NYSE: STJ) hat heute bekannt gegeben, dass die Einführungsgeräte der Typen Engage™ und Engage TR™ die Freigabe der US-Gesundheitsbehörde (Food and Drug Administration - FDA) und die Zulassung zum europäischen CE-Zeichen erhalten haben. Einführungsgeräte sind der Startpunkt für Herzkatheter bei Prozeduren für Diagnose und Eingriffe. Sie helfen dem Arzt, Zugang zu den Gefäßen zu bekommen und beizubehalten.

Federal tax policies should incentivize commercial deployment of advanced industrial biotechnologies, which can create jobs, reduce reliance on petroleum, and achieve greenhouse gas reductions. The Biotechnology Industry Organization (BIO) today released a white paper on the growth and jobs potential of green chemicals and briefed Congressional staff on the commercial status of industrial biotechnologies for algae applications, biobased products, and advanced biofuels.

Fox Systems today issued a statement that it is not related to Fox Insurance Company. The Centers for Medicare & Medicaid Services (CMS) recently announced that effective March 9, 2010, it terminated a contract with Fox Insurance Company, which provided services under the Medicare Part D program in 21 states. The Affiliated Fox Group, Inc. (AFGI), the former holding company for Fox Systems, sold all of its interests in Fox Insurance Company and its Part D contract with CMS, to Fox Rx, Inc., a New York based firm, in February 2006. Since this divestiture, Fox Systems has had no role for the provision of services under the Medicare Part D program, including any of the alleged program violations identified by CMS.

PSRx Advisors, LLC and MetaStar Inc. are partnering to provide Data Validation Readiness (DVR) assessments as mandated requirements from the Centers for Medicare & Medicaid Services (CMS) begins to bear down on Plan Sponsors of Medicare Advantage (Part C) and pharmacy benefit (Part D) programs.

As part of continuing efforts to help consumers find long-term care (LTC) insurance solutions that best meet their diverse needs, MetLife today announced that it has introduced Tiered Solution ^SM, a graded automatic inflation protection rider available with MetLife LTC LifeStage Advantage ^SM.

Healthways, Inc. (NASDAQ:HWAY) today announced that its financial results for the first quarter ended March 31, 2010 will be released after market close on Thursday, April 22, 2010, followed the same day by a conference call and live webcast scheduled for 5:00 p.m. ET.

Quintiles has expanded its capacity in Africa with the opening of an office in Nairobi, Kenya. A team of locally-based clinical professionals will monitor throughout East Africa, enhancing Quintiles capability to provide clinical research services across the continent.

Research and Markets (http://www.researchandmarkets.com/research/61226a/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Cognitive Impairment Associated with Schizophrenia" to their offering.

Research and Markets (http://www.researchandmarkets.com/research/3434cb/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Attention-Deficit/Hyperactivity Disorder" to their offering.

OXIS INTERNATIONAL, INC. (OTCBB: OXIS, Paris: OXI), a Company with significant intellectual property and patents in the field of oxidative stress and developer of products for nutraceutical, cosmeceutical and disease prevention caused by oxidative stress/inflammation, announced that OXIS' application to re-list on the bulletin board has been approved and the Company's shares are now available for trading on the OTC bulletin board with the symbol: OXIS.OB. OXIS common stock was previously quoted on the Pink Sheets.

Research and Markets(http://www.researchandmarkets.com/research/9862af/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2009: Physician Insights on Key Attributes: Prostate Cancer (Metastatic Hormone-Refractory )" to their offering.

Wendy R. Fleishman of the national plaintiffs' law firm Lieff Cabraser Heimann & Bernstein, LLP, announced today that Todd Lovelace and Christine Walker have filed separate personal injury lawsuits against Zimmer Holdings, the nation's largest producer of orthopedic devices. Lovelace and Walker seek respective damages against Zimmer for multiple surgeries and debilitating injuries they suffered due to the defective Durom Acetabular Component, an artificial hip socket known as the Durom Cup, which is manufactured and sold by Zimmer. First on the U.S. market in 2006, the Durom Cup was implanted in 12,000 patients.

Quotit^® Corporation, a division of The Word & Brown Companies, today introduced enhancements to their Internet system that will provide individuals and families seeking health insurance a seamless, online application for coverage.

While Florida has the second highest cancer burden in the nation, the state has only one National Cancer Institute. Successfully applying for NCI designation must include a commitment for additional funding from the state. The Sylvester Comprehensive Cancer Center is launching "We Tackle Cancer" bringing attention to the critical need for a second NCI.

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company has developing a long-term, room temperature, storage-stable form of its vaccines. This would replace the current requirement to keep the product frozen at -70^o C before use.

Mit der Eröffnung einer Niederlassung in Nairobi, Kenia, hat Quintiles seine Expansion in Afrika fortgeführt. Ein Team klinischer Experten vor Ort wird die Aufsicht in ganz Ostafrika übernehmen. Dadurch wird die Leistung von Quintiles bei der Bereitstellung klinischer Forschungsdienste auf dem gesamten Kontinent verbessert.

After the successful rollout of its clinical documentation and communication platform in the Southeast, Entrada has received venture funding to market the solution nationally to medical groups, hospitals, and electronic health record companies.

Dedicated to keeping area physicians ahead of the curve, Marquette General Health System (MGHS) will work with McKesson to deploy electronic health record (EHR) technology designed to help improve patient care throughout Michigan's Upper Peninsula. The region's only tertiary care provider plans to use McKesson's Practice Partner^® EHR, which integrates with the McKesson Paragon^® hospital information system (HIS) currently supporting Marquette General Hospital and its 30 owned physician practices.

Cox Smith Matthews Incorporated ("Cox Smith") today announced the immediate availability of its healthcare practice to provide counseling to companies in Texas who may be subject to a RAC review.

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration (FDA) to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek^®. The Phase 3 clinical study (NEO3-05) was conducted in subjects diagnosed with either breast cancer or melanoma. The FDA review included the efficacy and safety results of the NEO3-05 study and Neoprobe's plans for the submission of a New Drug Application (NDA) for Lymphoseek. The NDA submission will be based on the clinical results of NEO3-05 and other already completed clinical evaluations of Lymphoseek. FDA encouraged Neoprobe to request a series of pre-NDA meetings in the coming months to review the components of the NDA prior to its formal submission. Neoprobe indicated to FDA that the Company plans to submit the NDA following satisfactory completion of these meetings.

McCormick & Company, Incorporated (NYSE:MKC) is expanding a March 5, 2010 recall to include additional "Best By" dates of products manufactured with HVP (hydrolyzed vegetable protein) supplied by Basic Food Flavors of Las Vegas, Nevada, because the ingredient has the potential to be contaminated with Salmonella.

Standard Process Inc. awarded $10,000 in student scholarships at the National Chiropractic Legislative Conference (NCLC), held in Washington D.C., February 24-27, 2010.

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements, today announced financial and business results for the quarter and year ended December 31, 2009.

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it will hold a conference call tomorrow, Friday, March 12, 2010 to discuss the positive outcomes of a recent meeting with the United States Food and Drug Administration (FDA) regarding the clinical trial results of a Phase 3 investigational new drug, Lymphoseek^®, and the development pathway for a new drug application for Lymphoseek. The Phase 3 clinical study (NEO3-05) was conducted in subjects diagnosed with either breast cancer or melanoma.

Despite statistics stating that colorectal cancer is the fourth most frequently diagnosed cancer in men and women in the United States, mortality from colon cancer has decreased slightly over the past 30 years, possibly because of earlier diagnoses through screening and better treatment modalities. Recommendations relating to the latest treatment options were recently highlighted by Paul F. Engstrom, MD, of Fox Chase Cancer Center and chair of the NCCN Guidelines Panel for Colon and Rectal Cancer at the NCCN 15^th Annual Conference on March 11, 2010.

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex, will present on Tuesday, March 16^th, at 8:30 a.m. PDT at the 22^nd Annual Roth Capital OC Growth Stock Conference taking place at The Ritz-Carlton, Laguna Niguel in Dana Point, CA.

AIDS Healthcare Foundation (AHF) will host a media availability today, Thursday, March 11^th to discuss its filing of an appeal in its lawsuit against the Los Angeles County Department of Public Health (DPH) to require condom use or other reasonable steps to protect actors in the production of pornography in Los Angeles County. AHF filed the appeal with the California Second Appellate District (Appellate Case No: pending) Thursday morning.

The 9th Annual International Bioethics Forum, "Taking the Measure of the Magic Mirror: Toward a Science of Consciousness" will be held April 22-23, 2010 in Madison, WI.

PURE Bioscience (NASDAQ:PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported product revenues for the fiscal second quarter ended January 31, 2010 of $327,000, up from product revenues of $34,800 in the same quarter of the prior fiscal year. The Company reported a net loss of $1,766,200 or $(0.05) per share for the current quarter, improved from a net loss of $2,219,800 or $(0.07) per share in the second fiscal quarter last year.

A.M. Best Co. has posted video playback and a transcript of a one-hour webinar held on March 4. The webinar included analysts and industry experts who reviewed the financial performance of U.S. not-for-profit hospitals and health care systems.

In the immediate aftermath of the Haiti earthquake, teams from Air Liquide in the U.S., the Dominican Republic and Trinidad and Tobago acted quickly to bring life-saving medical oxygen to Haiti. Air Liquide teams established portable medical oxygen filling systems in Haiti to provide for the medical needs critical to relief efforts.

The Human Papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer, but is also associated with several other types of cancer. Expert physicians from NCCN Member Institutions presented an update on HPV and its link to various cancers including cervical cancer, anal carcinoma, and head and neck cancers discussing prevention strategies and the latest recommended treatment options according to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™).

Del Global Technologies Corp. (OTCBB: DGTC) ("Del Global" or "the Company") today announced financial results for its fiscal 2010 second quarter and six months ended January 30, 2010.

Obagi Medical Products, Inc. (NASDAQ: OMPI) today reported net revenue for the fourth quarter ended December 31, 2009 rose 21% to $30.7 million, from $25.4 million in the fourth quarter of 2008. The increase was due primarily to increased consumer and account confidence in the economy, international growth and higher product demand in advance of a January 1, 2010 price increase. Domestic and international sales represented approximately 81% and 19% of fourth quarter revenue, respectively.

Bioject Medical Technologies Inc. (OTCBB: BJCT), a leading developer of needle-free injection therapy systems, announced today that the Company will report its financial results for the fourth quarter and full year ended December 31, 2009 on Wednesday, March 17, 2010, after the close of the financial markets. Management will conduct a conference call on Thursday, March 18, 2010 at 10:00 a.m. Eastern Time to review the results for the quarter and the year. Ralph Makar, President and CEO, Dr. Richard Stout, Executive Vice President and Chief Medical Officer, and Chris Farrell, Vice President of Finance, will be hosting the call.

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported its results for the fourth quarter and full year 2009. The company also reported that based on the current pre-randomization dropout rate, there are a sufficient number of patients enrolled, scheduled or identified to achieve the 86-patient randomization target in STEPS, a Phase 3 registration study of GATTEX^® (teduglutide) in parenteral nutrition (PN) dependent short bowel syndrome (SBS).

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone. In addition, the SUN 1099 Phase 3 study of sunitinib plus capecitabine, in previously-treated advanced breast cancer patients, did not show a statistically significant improvement in progression-free survival compared with capecitabine alone.

Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC). An independent Data Safety Monitoring Committee (DSMC) recommended A4021018 be stopped after concluding that the addition of figitumumab to erlotinib is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to erlotinib alone in the study population.

Allstar Restaurants (OTC Bulletin Board: AREN) ("Allstar" or the "Company"), today announced changes to its Board of Directors.

Recent reports suggesting a link between long-term bisphosphonate usage and rare bone fractures have sparked rising concern among patients, health care professionals and the public. The American Society of Bone and Mineral Research (ASBMR) is examining this urgent clinical issue and will present its findings later this year.

UnitedHealthcare and The DAISY Foundation presented The DAISY Award for Extraordinary Nurses at Swedish Medical Center in Seattle. This unique recognition program is part of many hospitals' recruitment and retention programs, helping to offset the acute shortage of nurses nationwide. Each month, nurses are selected by their nursing administration and peers to receive The DAISY Award. The honorees receive a certificate commending her/him for being an "Extraordinary Nurse." The certificate reads: "In deep appreciation of all you do, who you are, and the incredibly meaningful difference you make in the lives of so many people." Matthew Bouthillier, RN, Issaquah campus who died while on a volunteer medical relief mission to Haiti was given special recognition.

Baxter International Inc. (NYSE:BAX), in conjunction with DynPort Vaccine Company LLC (DVC), a CSC Company (NYSE:CSC), today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter's Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

National Health Investors, Inc. (NYSE:NHI) announced today a total of $29.7 million in purchase/leaseback transactions. The transactions include three assisted living and memory care facilities totaling 102 units in Minnesota with Suite Living Senior Specialty Services (formerly known as Comforts of Home) for $17.2 million and a 66-bed acute psychiatric hospital known as Alvarado Parkway Behavioral Institute in La Mesa, California with Helix Healthcare for $12.5 million. The purchases were funded with borrowings from NHI's revolving credit facility. The transactions will bring NHI's total investments to date in 2010 to $96.7 million.

Attorney Mike Williams announced today a lawsuit filed by Sharron Selman, Joan Tope and Linda Narz, who want doctors to stop prescribing the hormone replacement drug Prempro and its active ingredients. At the same time, they want doctors to start informing patients about a safe alternative.

Akorn, Inc. (NASDAQ: AKRX) a niche generic pharmaceutical company, announced today that it has entered into an agreement to issue and sell to Serum Institute of India Ltd. ("Serum") 1,838,235 shares of the Company's common stock at $1.36 per share or a 15% discount to the market closing price on March 5, 2010 of $1.60 per share, resulting in aggregate proceeds of $2,500,000. The Company also agreed to issue to Serum a warrant to purchase approximately 1,404,494 additional shares of the Company's common stock for cash at an exercise price of $1.78 per share, which would result in an additional aggregate proceeds of $2,500,000. The warrant is exercisable beginning on the fifth consecutive trading day that the closing price of the Company's common stock is at least $2.22 per share. The warrant expires 30 days after it becomes exercisable or on March 10, 2013, whichever comes first. The shares issued to Serum are subject to registration rights.

Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been named by the World Trade Center Institute (WTCI) as one of Maryland's outstanding international business leaders. Celebrating the spirit of global ambition and excellence in international leadership, WTCI presents the Maryland International Leadership Awards annually to leaders within the state who exemplify entrepreneurial spirit, innovation, and global reach.

Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $1.25 billion of its 3.0 percent Senior Notes due 2015, $1.25 billion of its 4.45 percent Senior Notes due 2020 and $500 million of its 5.55 percent Senior Notes due 2040 (collectively, the "Notes"). Medtronic intends to use the net proceeds for working capital and general corporate purposes, which may include the repayment of its indebtedness.

Dohmen Company CEO, Cynthia (Dohmen) LaConte announced today that the Dohmen Company Foundation, the philanthropic arm of the 152-year-old healthcare services company has donated $500,000 to Map International to assist the organization in its efforts to fight neglected tropical diseases (NTD's).